All In Biotech

Drug Trial Radar · NCT06801353

A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps

Last checked: Nov 19, 2026Latest source record: Feb 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Feb 1, 2025

Primary completion

Dec 1, 2025

Study completion Jul 1, 2026

Sponsor

Lead sponsor
Beijing Tongren HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Recently, several biologic therapies have become available for treating chronic rhinosinusitis with nasal polyps (CRSwNP). However, not every patient responds to these treatments. This clinical trial aims to develop a non-invasive predictive model to help determine how effective IL-4Rα targeted monoclonal antibody therapy will be for individuals with CRSwNP.

Conditions

  • Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
  • Biological Therapy
  • Biomarkers

Interventions

  • StapokibartBiological

    Stapokibart subcutaneously every two weeks

  • Mometasone Furoate Nasal Spray (MFNS)Drug

    mometasone furoate nasal spray 200 μg once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Nasal Polyps Score (NPS)Time frame: week 16
  2. Nasal Congestion Score (NCS)Time frame: week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.